XML 70 R54.htm IDEA: XBRL DOCUMENT v3.6.0.2
Major Customers and Concentration of Credit Risk (Details) - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Concentration Risk [Line Items]      
Revenue $ 35,368,361 $ 40,572,111 $ 10,456,766
Revenue | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 100.00% 100.00% 100.00%
MedImmune      
Concentration Risk [Line Items]      
Revenue $ 1,518,639 $ 16,037,731 $ 0
Accounts receivable $ 1,200,000 $ 1,500,000  
MedImmune | Revenue | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 4.00% 40.00% 0.00%
MedImmune | Accounts Receivable | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 7.00% 20.00%  
DARPA      
Concentration Risk [Line Items]      
Revenue $ 26,602,183 $ 11,582,623 $ 123,605
Accounts receivable 12,100,000 $ 4,000,000  
Unbilled receivables $ 6,800,000    
Estimated collection period for unbilled receivables 12 months    
DARPA | Revenue | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 75.00% 28.00% 1.00%
DARPA | Accounts Receivable | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 73.00% 54.00%  
Roche      
Concentration Risk [Line Items]      
Revenue $ 4,917,929 $ 10,778,688 $ 7,357,346
Accounts receivable $ 2,400,000 $ 1,600,000  
Roche | Revenue | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 14.00% 27.00% 70.00%
Roche | Accounts Receivable | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 15.00% 22.00%  
NIAID      
Concentration Risk [Line Items]      
Revenue $ 118,171 $ 901,475 $ 1,229,084
NIAID | Revenue | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 0.00% 2.00% 12.00%
GeneOne (affiliated entity)      
Concentration Risk [Line Items]      
Revenue $ 1,188,432 $ 450,000 $ 479,464
GeneOne (affiliated entity) | Revenue | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 4.00% 1.00% 5.00%
All other      
Concentration Risk [Line Items]      
Revenue $ 1,023,007 $ 821,594 $ 1,267,267
All other | Revenue | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 3.00% 2.00% 12.00%
Minimum | DARPA      
Concentration Risk [Line Items]      
Age of unbilled receivables 1 month    
Maximum | DARPA      
Concentration Risk [Line Items]      
Age of unbilled receivables 9 months